Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

survival between the two arms despite substantial improvement in secondary endpoints.

"We intend to use the results of this study to further understand the potential of ERBITUX in the treatment of colorectal cancer patients." said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb.

The EPIC trial (ERBITUX Plus Irinotecan in Colorectal Cancer) enrolled 1,298 irinotecan-naive mCRC patients whose disease was not responding to first-line oxaliplatin-based chemotherapy. After randomization, patients were treated until their disease progressed. Upon disease progression, study treatment was stopped and further treatment was at the discretion of the physician. Patients who received combination ERBITUX plus irinotecan experienced median overall survival of 10.71 months and median progression- free survival of 4 months; in this treatment group, overall response rate was achieved in 16.4% of patients and 61.4% of patients experienced disease control. Patients who received irinotecan alone experienced median overall survival of 9.99 months and median progression-free survival of 2.6 months; in this treatment group, overall response rate was achieved in 4.2% of patients and 45.8% of patients experienced disease control.

Grade 3/4 adverse events included rash (ERBITUX-irinotecan arm: 8.2% vs. irinotecan arm: 0.5%), infusion reaction (1.4% vs. 0.8%) and hypomagnesemia (3.3% vs. 0.4%). Other common non-hematologic adverse events included: diarrhea (28.8% vs. 16.2%) and fatigue (9.2% vs. 4.9%).

About Colorectal Cancer

In the U.S., approximately 154,000 people will be diagnosed with cancer of the colon or rectum this year. Half of these patients have metastatic disease, or cancer that has spread to other organs, at the time of diagnosis. EGFR is expressed in up to 77.7 % of colorectal cancer tumors. Colorectal cancer is the third most common cancer in both men and women.

About ERBITUX(R) (Cetuximab)<
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... 2014  In part four of a ... pharmacy as a strategic asset, Mary Baxter, MBA, ... Cardinal Health,s Innovation Delivery Solutions business, discusses how expanding ... hospitals and patients. "Every hospital pharmacist knows ... their job in a value-based healthcare world," Baxter says. ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... , June 22 Xoft, makers of ... today announced the integration of its Axxent® Electronic Brachytherapy ... of the art, fully comprehensive breast center exclusively dedicated ... cancer. The Pink Lotus Breast Center is the first ...
... The SCOOTER Store today announced a major milestone, saying it has provided ... wheelchair to Earvin Thompson of Houston, Texas . Ms. ... provider of power mobility equipment, will enjoy more freedom and independence with ... , ...
Cached Medicine Technology:Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4
(Date:9/1/2014)... 2014 Psychogenic Non-epileptic Seizures (PNES), also ... disorder that can have devastating effects on those who ... seizures however, they are not produced by electrical anomalies ... It is estimated that the numbers of persons suffering ... sclerosis. , Dr. Lorna Myers, Director of ...
(Date:8/31/2014)... MedixSafe has become very popular in ... narcotics lockers . Electronic Security Specialists ... distribution worldwide. “We have now shipped multiple orders to ... Sales Manager , MedixSafe is a division of Electronic ... cabling company with over 30 years in the security ...
(Date:8/31/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo products, ... bamboo veneers . Additionally, it has deiced offer autumn discounts( ... products. The promotion will last from today until September 16. ... quality veneers are hot in the global market. “We are ... All these items are made according to our latest study ...
(Date:8/31/2014)... With years of hard work, Delta has now ... machines. Recently, the company has updated its wheel loader ... loaders. All these items are guaranteed to be great. Additionally, ... , It is true that all items in Delta’s ... machine specialists. The firm is making full efforts to help ...
(Date:8/31/2014)... Asked to offer tips for consumers ... "absorption," Dr. Priya Khan, Director of Research & ... "Bioavailability" and "absorption" are possibly the most misused, ... second perhaps only to the confusion over food-based ... related, are not the same. Bioavailability refers to ...
Breaking Medicine News(10 mins):Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:High Quality Bamboo Veneers from Bambooindustry.com Receive International Attention 2Health News:Delta Updates Its Wheel Loader Assortment With A Lot Of Cheap Used Cat 966 Loaders 2Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 2Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 3Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 4
... NEW BRUNSWICK, N.J., May 13 Johnson & Johnson ... Deutsche Bank 34th Annual Health Care Conference on Tuesday, ... Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group for Johnson ... scheduled at 10:50 a.m. (Eastern Time).This broadcast will be ...
... 13 Accumetrics, Inc. announces that it has enrolled ... ( G auging R esponsiveness with A ... hrombosis A nd S afety). The trial ... clinicians with actionable information for patients who are poor ...
... Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or ... pharmaceutical grade,glucose products in China, today announced that ... ended March 31, 2009 after the close of ... Management will conduct a conference call,on Friday, May ...
... (Nasdaq: ESRX ) announced that it will present ... May 19, 2009 at 10:10 a.m. EDT at the InterContinental ... the Internet and can be accessed on the investor relations ... RealPlayer or Windows Media Player is needed to listen ...
... Winner Medical Group Inc.,(OTC Bulletin Board: WMDG) ("Winner Medical", or ... ended March 31,2009. The Company,s results are detailed in its ... Commission. , , Second Quarter 2009 Highlights, ... 15.31% over the second quarter of, ...
... expression and activity of Cystathionase is reduced in ... and impaired generation of hydrogen sulphide, two factors ... resistance. , In the present study the analysis ... presence of an inverted repeat sequence. Administration of ...
Cached Medicine News:Health News:Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial 2Health News:Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call 2Health News:Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call 3Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 2Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 3Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 4Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 5Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 6Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 7Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 8Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 9Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 10Health News:Winner Medical Reports Second Quarter Fiscal 2009 Results 11Health News:Farnesoid X receptor regulates cystathionase 2
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... sulfate ester of DHEA, derived from sulfated ... in adrenal and extradrenal tissues. DHEA is ... adrenal cortex, and is a precursor for ... weak androgenic activity, which for unsulfated DHEA ...
Inquire...
Medicine Products: